Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $173.912 million which beat the analyst consensus estimate of $169.677 million by 2.50 percent. This is a 69.41 percent increase over sales of $102.660 million the same period last year.